

Under the aegis of



**D&CVD**




**3<sup>rd</sup> EDITION**  
**Update on Diabetes**  
**and CVD**

**Meeting in cooperation**  
**between:**  
**D&CVD Study Group**

*(Reference Study Group of EASD)*  
*IRCCS MultiMedica, Milan*

**16<sup>th</sup>-17<sup>th</sup> January 2026**

**PAVIA**  
**Collegio Ghislieri**





## SCIENTIFIC RATIONALE

The presence of hyperglycemia associated with the well-known risk factors of metabolic syndrome and diabetes itself predispose to important cardiovascular complications which have a strong impact on the quality of life of the individual and on the community in general, also from an economic point of view. The cardio-vascular-renal complications of diabetes still represent the major cause of mortality and disability of people affected by it, resulting in hospital admission in over 75% of cases.

In recent years, we have available different categories of drugs with proven effects of positive action on the significant reduction of cardiovascular and renal events; recommended consequently in national and international guidelines, as early use for the treatment of diabetes.

It is of the utmost importance to assess cardiovascular risk in individuals with diabetes who do not yet have clinical evidence of cardiovascular disease, in order to identify those at the highest risk, in which maximum prevention must be immediately activated, correcting lifestyles and implementing the most appropriate therapy. From stratification of cardiovascular risk to screening, diagnosis and treatment. The new Guidelines for cardiovascular diseases, in people with diabetes, of the European Society of Cardiology (ESC), evaluate and summarize the available scientific evidence, with the aim of supporting health professionals in proposing the best diagnostic and therapeutic approach.

The purpose, therefore, of this course is to deepen and update the current knowledge of prevention of diabetes complications, with maximum interactivity between cardiologists and diabetologists; deepening the epidemiology and pathogenesis of renal and cardiovascular diseases, the possible mechanisms of action in the demonstrated prevention, the comparison of the different therapeutic approaches and the possible advantages of an early and more generalized use.



## 3<sup>rd</sup> EDITION Update on Diabetes and CVD

### Meeting in cooperation between: D&CVD Study Group

*(Reference Study Group of EASD)*

*IRCCS MultiMedica, Milan*

#### Scientific Directors

**Cesare Celeste Federico Berra**  
**Antonio Ceriello**  
**Bruno Solerte**

#### FACULTY

**Lucio Amoresano** Monza (IT)  
**Angelo Avogaro** Padova (IT)  
**Tadej Battelino** Ljubljana (SI)  
**Irene Bernardi** Monza (IT)  
**Cesare Celeste Federico Berra** Milan (IT)  
**Federico Bertuzzi** Milan (IT)  
**Antonio Carlo Bossi** Bergamo (IT)  
**Riccardo Candido** Trieste (IT)  
**Alberico Luigi Catapano** Milan (IT)  
**Daniela Ceccarelli Ceccarelli** Pesaro (IT)  
**Antonio Ceriello** Milan (IT)  
**Nadia Cerutti** Pavia (IT)  
**Stefano Ciardullo** Monza (IT)  
**Caterina Conte** Rome (IT)  
**Francesco Cosentino** Stockholm (SE)

**Nicola Cosentino** Milan (IT)  
**Gian Marco Dacquinio** Milan (IT)  
**Giulia Ferrannini** Stockholm (SE)  
**Amalia Gastaldelli** Siena (IT)  
**Andrea Giaccari** Rome (IT)  
**Francesco Giorgino** Bari (IT)  
**Per-Henrik Groop** Helsinki (FI)  
**Ernesto Maddaloni** Rome (IT)  
**Roberto Manfrini** Milan (IT)  
**Barbara McGowan** London (UK)  
**Marco Mirani** Milan (IT)  
**Laura Molteni** Como (IT)  
**Paola Muti** Milan (IT)  
**Emanuela Orsi** Milan (IT)  
**Dimitrios Papamargaritis** Leicester (UK)

**Roberto Pontremoli** Genoa (IT)  
**Francesco Prattichizzo** Milan (IT)  
**Giuseppe Pugliese** Rome (IT)  
**Veronica Resi** Milan (IT)  
**Cristina Romano** Varese (IT)  
**Giuseppe Rosano** London (UK)  
**Antonio Rossi** Milan (IT)  
**Giuseppina Russo** Messina (IT)  
**Bruno Solerte** Pavia (IT)  
**Roberto Trevisan** Bergamo (IT)  
**Luc Van Gaal** Antwerp (BE)  
**Roberto Vettor** Padua (IT)  
**Cristiana Vitale** Rome (IT)  
**Maurizio Volterrani** Rome (IT)  
**Michal Vrablik** Prague (CZ)

## DAY 1: JANUARY 16<sup>th</sup> 2026

### 09.00-09.30 Welcome and Introduction to The Meeting

*Antonio Ceriello (Chair D&CVD Study Group)*

*Paola Muti (Scientific Director IRCCS Multimedica)*

*Bruno Solerte (University of Pavia)*

### SESSIONE I:

#### 09.30-10.15 NEW GUIDELINES FOR THE MANAGEMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES

*Chairmen: Andrea Giaccari, Veronica Resi*

#### 09.30-09.45 IDF Global Recommendations for Type 2 management - Antonio Ceriello

#### 09.45-10.00 ADA/EASD 2026 - Francesco Giorgino

#### 10.00-10.15 Discussion

### SESSIONE II:

#### 10.15-11.15 CARDIO-RENAL DISEASE IN TYPE 1 DIABETES

*Chairmen: Salvatore De Cosmo, Cristina Romano*

#### 10.15-10.30 CVD in type 1 diabetes - Francesco Cosentino

#### 10.30-10.45 CKD in type 1 diabetes - Per-Henrik Groop

#### 10.45-11.00 What can we translate from type 2 to type 1 as therapeutic perspective?

*Roberto Pontremoli*

#### 11.00-11.15 Discussion

#### 11.15-11.45 Coffee Break

### SESSIONE III:

#### 11.45-12.45 WEIGHT MANAGEMENT AND POSSIBLE SIDE EFFECTS

*Chairmen: Marco Mirani, Roberto Vettor*

#### 11.45-12.00 Weight management in obesity

*Luc Van Gaal*

#### 12.00-12.15 Weight management in type 2 diabetes: new perspective with the role of double agonism GIP/GLP1 - Caterina Conte

#### 12.15-12.30 Weight management in type 1 diabetes

*Ernesto Maddaloni*

#### 12.30-12.45 Discussion

#### 12.45-14.00 Lunch

### SESSIONE IV:

#### 14.00-15.00 CARDIO-RENAL DISEASE IN TYPE 2 DIABETES

*Chairmen: Lucio Amoresano, Giuseppe Pugliese*

#### 14.00-14.15 How cardiologists can manage excess body weight and related cardiovascular risk

*Giuseppe Rosano*

#### 14.15-14.30 The link between heart failure and kidney disease: how to face diabetes?

*A cardiologist point of view - Maurizio Volterrani*

#### 14.30-14.45 The link between heart failure and kidney disease: how to face diabetes?

*A diabetologist point of view - Angelo Avogaro*

#### 14.45-15.00 Discussion

### 15.00-16.00 LECTURES

*Chairmen: Antonio Ceriello, Bruno Solerte*

#### 15.00-15.30 The reality of diabetes remission

*Dimitrios Papamargaritis*

#### 15.30-16.00 The link between diabetes, cancer and CVD

*Paola Muti*

## SESSIONE V:

### 16.00-17.00 **NEW RISK FACTORS FOR CVD**

*Chairmen: Nicola Cosentino, Roberto Manfrini*

### 16.00-16.15 **Emerging role of micro and nano-plastics in CVD** - Francesco Prattichizzo

### 16.15-16.30 **MASLD/NASH and CVD** - Amalia Gastaldelli

## DAY 2: JANUARY 17<sup>th</sup> 2026

## SESSIONE VI:

### 09.00-10.00 **WHAT'S NEW ON DEVICES AND MONITORING IN TYPE 2 DIABETES**

*Chairmen: Stefano Ciardullo, Emanuela Orsi*

### 09.00-09.15 **How can CGM help?** - Tadej Battelino

### 09.15-09.30 **Platforms and devices: how can help in type 2 diabetes** - Antonio Rossi

### 09.30-09.45 **Adherence and technology: new possibility for old problems** - Federico Bertuzzi

### 09.45-10.00 **Discussion**

## SESSIONE VII:

### 10.00-11.00 **NEW INSIDE FOR OLD PROBLEM**

*Chairmen: Riccardo Candido, Nadia Cerutti*

### 10.00-10.20 **Autophagy as a potential target for drug repurposing in age-associated metabolic disorders** - Daniela Ceccarelli Ceccarelli

### 10.20-10.35 **10 years of CVOT with GLP1-RA: still new?** Cesare Berra

### 10.35-10.50 **Oral GLP1: an update** - Irene Bernardi

### 10.50-11.00 **Discussion**

### 11.00-11.30 **Coffee Break**

### 16.30-16.45 **Experience from EUROASPIRE**

*Giulia Ferrannini*

### 16.45-17.00 **360° diabetes care: SGLT2i for Holistic Diabetes Prevention** Cesare Berra

### 17.00-17.15 **Discussion** **End of day one**

## SESSIONE VIII:

### 11.30-12.30 **DIABETES AND LIPIDS**

*Chairmen: Alberico Catapano, Laura Molteni*

### 11.30-11.45 **Dyslipidemia in patients with diabetes: what's new in the EAS/ESC 2025 guidelines** Michal Vrablik

### 11.45-12.00 **iPCSK9 bempedoic acid and cardiovascular risk control in patients at high risk: Ldl-C Target and role of statins** - Gian Marco Dacchino

### 12.00-12.20 **Diagnosis of vascular complication in Type 2** Cristiana Vitale

### 12.20-12.30 **Discussion**

## SESSIONE IX:

### 12.30-13.30 **NEW PERSPECTIVE**

*Chairmen: Antonio Bossi, Fabio Buzzetti*

### 12.30-12.45 **New insulins** - Roberto Trevisan

### 12.45-13.00 **New therapies for the treatment of diabetes and obesity** - Barbara McGowan

### 13.00-13.15 **How early and how long should be the use of SGLT-2i and GLP1-RA?** - Giuseppina Russo

### 13.15-13.30 **Discussion**

### 13.30-14.00 **Closing remarks and take-home messages** Cesare Berra, Antonio Ceriello, Bruno Solerte

### 14.00 **End of meeting**

**DATE:** 16<sup>th</sup>-17<sup>th</sup> January 2026

**VENUE:** Collegio Ghislieri, Piazza Collegio Ghislieri, 5 - 27100 Pavia

**ORGANIZING SECRETARIAT & CME PROVIDER - 181**

**dynamicom**  
**education**  
Passione per i valori

ECM  
European Certificate of  
Mastery  
Assessment Provider 181

Management  
System  
USAFH 125-2022  
dynamicom.com  
certificazioni

ecovadis

In collaborazione con  
empethy

**D&CVD**

PROVIDER ECM STANDARD accreditato presso la Commissione Nazionale per la Formazione Continua in Medicina del Ministero della Salute con numero 181.

MIND DISTRICT - The Hive/H2 - Viale Decumano 36, 20157 Milan

giada.giuliani@dynamicom-education.it



The meeting will be accredited for the Italian physicians, in accordance with the existing national laws on CME.

**Profession:** Physicians and Nurse **Reserved to the following categories:** Metabolic Diseases and Diabetology, Endocrinology, Cardiology, Geriatrics, Internal Medicine. **Number of participants:** 200 **Training objective:** n. 3 **Assigned CME credits:** 8, 4 **Official meeting languages:** Italian and English

### REGISTRATION PROCEDURE

1. Go to the website **www.dynamicomeducation.it**.
2. If this is your first time accessing the platform, click on **"Register"** either in the top menu or at the bottom of the homepage, and complete the registration form with your personal details.
3. A confirmation email will be automatically sent to the address you provided.
4. Log in to the website using your personal credentials.
5. Click on the following link: <https://dynamicomeducation.it/event/update-on-diabetes-3rd-2026> or use the Search function to find the course titled **"UPDATE ON DIABETES AND CVD: 3<sup>RD</sup> EDITION MEETING IN COOPERATION BETWEEN"**, then click the "Register" button.
6. After attending the in-person course, log in to the platform using your credentials and complete the evaluation questionnaires within 72 hours.

The ECM certificate will be available on the platform within 90 days after the end of the event, provided the questionnaire is passed and at least 90% of the scientific sessions have been attended.

For technical assistance, click the **"Support"** box on the homepage and fill out the form.

## 3<sup>rd</sup> EDITION Update on Diabetes and CVD

**Meeting in cooperation between:  
D&CVD Study Group**  
(Reference Study Group of EASD)  
IRCCS MultiMedica, Milan

*With the unconditional support of:*

**ASTRAZENECA**  
**BAYER AG**  
**BOEHRINGER INGELHEIM**  
**LABORATORI GUIDOTTI**  
**PIAM FARMACEUTICI**

*Thanks to the following sponsor companies for the printing:*



Menarini, soluzioni per il domani

